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Abstract
Background: The objective was to examine the short-term risk and predictors of anaemia following initiation of
combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern
Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International
Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration.
Methods: Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with
three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests.
Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and
stratified by IeDEA region.
Results: Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests
(7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-
Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in
45% of Western Africa patients, 29% of Eastern Africa patients, 21% of Southern Africa patients, 36% of Central
Africa patients, 15% of patients in Asian-Pacific and 14% of patients in Caribbean and Central and South America.
Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7,
22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian,
and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female
sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART
containing zidovudine.
Conclusions: In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America,
and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring
was recommended in patients at risk of developing anaemia following cART initiation.
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According to World Health Organization (WHO) esti-
mations [1], access to combination antiretroviral treat-
ment (cART) has improved dramatically in low- and
middle-income countries with limited resources. At the
end of 2009, almost 5.3 million people were receiving
antiretroviral therapy in low- and middle-income coun-
tries, an increase of more than 1.2 million people from
December 2008. In addition, with the newly updated
treatment guidelines, the number of people estimated to
be in need of cART increased from 10 million to close
to 15 million at the end of 2009.
Zidovudine (AZT) was recommended by WHO [2] as
a first-line regimen in combination with another nucleo-
side reverse transcriptase inhibitor (NRTI) and a non-
nucleoside reverse transcriptase inhibitor (NNRTI). AZT
was also used as an alternate for patients switching from
stavudine (d4T) to AZT due to toxicity, or as part of the
treatment programme’s systematic effort to avoid long-
term toxicity issues associated with d4T toxicity [3,4].
The 2010 WHO guidelines recommend that countries
using d4T in their first-line regimens phase d4T out and
replace it with either AZT or tenofovir in order to pre-
vent long-term toxicity [2].
There have been reports of the short-term tolerability
related to the use of AZT, in particular the development
or worsening of anaemia. Anaemia was associated with
previous clinical AIDS disease or other infection, CD4
count, HIV viral load, female sex, age, and low body
mass index [5-7]. Given the recent change in WHO
guidelines, there was some concern that rates of anae-
mia may increase with the transition from d4T-contain-
ing regimens to AZT-containing regimens.
The objective was to examine the short-term risk and
predictors of anaemia following initiation of cART in
HIV-infected patients from the Western Africa (WA),
Eastern Africa (EA), Southern Africa (SA), Central
Africa (CA), Asian (TA) and Caribbean and Central and
South America (CSA) regions of the International Epi-
demiologic Databases to Evaluate AIDS (IeDEA)
collaboration.
Methods
Study population: the IeDEA collaboration
The IeDEA initiative of the U.S. National Institutes of
Health has established international regional centres for
the collection and harmonization of data and the estab-
lishment of an international research consortium to
address unique and evolving research questions in HIV/
AIDS currently unanswerable by single cohorts [8]. Clini-
cally derived HIV treatment data is being collected by
researchers throughout the world. This initiative provides
a means to establish and implement methodologies to
effectively pool the collected data from regions around
the globe, thus providing a cost-effective means of gener-
ating large data sets to address high-priority research
questions related to HIV/AIDS care.
By developing a proactive mechanism for the collec-
tion of key variables, this initiative will enhance the
quality cost effectiveness and speed of HIV/AIDS
research. The sources that support the IeDEA research
agenda include independently funded investigators and
clinical networks, domestic and international cohorts,
individual clinicians caring for large numbers of HIV-
infected persons, and national or local databases. Cur-
rently, there are seven IeDEA regions: Canada and Uni-
ted States; Caribbean and Central and South America;
Asia and Pacific; Western Africa; Central Africa; Eastern
Africa; and Southern Africa. Data from more than
300,000 HIV-infected persons from 38 different coun-
tries are currently included under this initiative. Details
of the IeDEA initiative can be found at http://www.
iedea.org/. The IeDEA regions that participated in this
analysis were the Western Africa [9], Southern Africa
[10] and Eastern Africa [11], Central Africa [12], Asia-
Pacific regions [13] and Caribbean and Central and
South America [14].
Adult patients (age > 18 years) were included if they
initiated cART regimens that contained three or more
drugs and had haemoglobin levels above 10 g/dL within
90 days prior to cART initiation, and at least one fol-
low-up haemoglobin test.
Procedures and statistical analysis
Study procedures
The concept for this analysis was reviewed and
approved by the IeDEA Executive Committee and all
the participating regional steering committees. The data
elements in this analysis included baseline and demo-
graphic data, HIV disease staging according to
Centers for Disease Control and Prevention (CDC)
and/or WHO classification, CD4 and HIV viral load
testing, antiretroviral treatment, haemoglobin testing,
and weight and height measurements. The regional data
centres reviewed and extracted the requested data from
their regional databases or requested the identified vari-
ables from designated programmes within their regions.
The data were then centrally aggregated and analysed at
The Kirby Institute in Sydney, Australia, the regional data
centre of the Asia-Pacific IeDEA region. Data consistency
checks were conducted when the data were received. This
included queries on apparent data-entry errors, out-of-
range testing results, antiretroviral treatment combinations
that fell outside of the standard of care (for example, AZT
concurrent with d4T), and possible data-entry error, such
as dates of starting and stopping cART.
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tion Working Groups, comprised of members from each
IeDEA region, facilitated the early stage of concept
development, as well as later data collection and pre-
paration of the analytical datasets.
Statistical analysis
We used the NIH Division of AIDS definitions for
Grading the Severity of Adult and Paediatric Adverse
Events [15]. Anaemia was defined as a haemoglobin
level of < 10 g/dL, and severe anaemia as a haemoglobin
level of < 7.5 g/dL.
Mean change of haemoglobin level from cART initia-
tion to 36 months was graphically represented in
patients with baseline and follow-up haemoglobin tests.
The proportions of patients with anaemia at month 12
after initiation of antiretroviral treatment were tabulated
by baseline haemoglobin level and stratified by initial
AZT or d4T use. Time to anaemia and severe anaemia
within 12 months of cART initiation was assessed by
survival analysis. Patients tested but not found to be
anaemic were censored at month 12. Factors associated
with anaemia were examined using Cox proportional
hazards models and stratified by IeDEA region.
Due to the fact that the proportions of patient initiating
AZT-containing cART were different across the IeDEA
regions, we further investigated the interaction term
between AZT use and IeDEA region in predicting anaemia
at 12 months. In these analyses, the risk factors for anae-
mia identified in the main Cox model, and their directions
and magnitude, remained largely the same, indicating the
robustness of our analyses (data not shown). The analysis
was performed using SAS (version 9.1, SAS Institute Inc.,
Cary, North Carolina, USA) and STATA (version 10.1,
StataCorp, College Station, Texas USA).
Results
The baseline characteristics are shown in Table 1. The
number of cohorts contributing patients varied between
IeDEA regions: 12 in WA, one in EA, seven in SA, 10 in
CA, one in TA, and three in CSA. A total of 19,947
patients initiated cART containing three or more drugs
and each had a baseline haemoglobin test and at least
one follow-up haemoglobin test (7358 in WA, 7289 in
EA, 2853 in SA, 471 in CA, 1550 in TA and 426 in
CSA).
Most patients included in this analysis started cART
in 2004 and 2005, except those from CA, who started
more recently (median 2009). There were more female
patients in WA, EA, SA and CA compared with TA and
CSA, which had a majority of male patients. In each
region, more than 40% of patients were aged between
30 and 39 years. The information on exposure was miss-
i n gi nm o r et h a n7 0 %o fp a t i e n t sf r o mW Aa n dE A ;
however, heterosexual contact is the most reported cate-
gory in all regions (Table 1).
At initiation, anaemia and severe anaemia were found
in 37% and 8% of patients from WA, 24% and 5% from
EA, 18% and 3% from SA, 33% and 3% from CA, 13%
and 2% from TA, and 12% and 2% from CSA, respec-
tively (Table 1). Within 12 months of cART initiation,
patients from WA, EA and CA had a median of one
haemoglobin test, patients from SA had two tests, and
patients from TA and CSA had three tests. The median
number of days from initiation to the first haemoglobin
test was 217, 212, 294, 104.5, 282 and 274 days in
patients from WA, EA, SA, CA, TA and CSA,
respectively.
At cART initiation, the patients in each region had
median CD4 counts between 101 and 148 cells/mm
3
and more than half of the patients did not have a base-
line HIV RNA test (Table 1). The proportion of patients
with either CDC stage three or WHO stage four varies
in different regions, from 9% in EA to 66% in CA.
Tuberculosis co-infection was reported in all regions,
ranging from 7% in CSA to 96% in CA. Use of co-tri-
moxazole (TMP-SMX) was reported in 60% of patients
in WA, 59% in EA and 52% in TA.
The most frequent cART regimen at treatment initia-
tion was a three-drug combination of two NRTIs (the
majority either with d4T+3TC or AZT+3TC), plus one
NNRTI (either with NVP or EFV). An AZT-containing
regimen was initiated in 35% of patients in WA, 4% in
EA, 26% in SA, 60% in CA, 40% in TA, and 79% in
CSA. In each of the IeDEA regions, patients with more
severe anaemia were generally more likely to initiate
with a non-AZT-containing regimen (Figure 1).
The mean change in haemoglobin from cART initia-
t i o ni ss h o w ni nF i g u r e2 .I np a t i e n t si n i t i a t i n gA Z T -
containing cART, there was an initial mean haemoglo-
bin decrease of approximately 0.5 g/dL in the first three
months; in patients starting with non-AZT-containing
cART, there was an immediate haemoglobin increase
after initiation. From three months after treatment
initiation, there was a mean difference of approximately
1 g/dL between patients initiating AZT-containing
cART and those initiating with non-AZT-containing
cART that persisted for up to 36 months.
A total of 13,445 (68%) patients initiated cART with
normal haemoglobin, 4057 (55%) in WA, 5142 (71%) in
EA, 2257 (79%) in SA, 304 (64%) in CA, 1317 (85%) in
TA, and 368 (86%) in CSA. Within 12 months of cART
initiation, the risks of severe anaemia were 3.9 per 100
person-years (95% confidence interval, CI, 3.6-4.2) and
varied from 2.3 (2.0~2.7) in EA to 10.2 (7.1~14.1) in
CA; the overall risks of any anaemia (including severe
anaemia) were 11.5 per 100 person-years (11.0, 12.1)
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West
Africa
Eastern
Africa
Southern
Africa
Central
Africa
Asia-
Pacific
Central & South
America
Total
No. cohorts in database 12 1 7 10 1 3 34
No. patients in database 14340 8992 3459 18047 4074 1644 50556
No. initiating cART with 3 or more antiretrovirals 12502 8971 3357 4715 3501 1644 34690
No. with haemoglobin at initiation 10823 7326 3265 2215 1754 460 25843
No. with follow up haemoglobin test 7358 7289 2853 471 1550 426 19947
(among patients with haemoglobin at initiation)
Year cART was initiated
Median (IQR) 05 (04,06) 05 (05,06) 05 (04,06) 09 (08,09) 04 (02,05) 04 (02,05) 05 (04, 06)
Gender
Male 2665
(36%)
2876
(39%)
672 (24%) 142 (30%) 1097
(71%)
270 (63%) 7722
(39%)
Female 4693
(64%)
4413
(61%)
2181 (76%) 329 (70%) 453 (29%) 156 (37%) 12225
(61%)
Age (years, at initiation)
Median (IQR) 37 (31,43) 38 (33,45) 34 (29,40) 39 (33,45) 35 (30,42) 37 (31,44) 37 (31,44)
< = 30 1661
(23%)
1176
(16%)
891 (31%) 72 (18%) 442 (27%) 99 (23%) 4321
(22%)
31~40 3116
(42%)
3054
(43%)
1257 (44%) 166 (36%) 669 (43%) 182 (43%) 8444
(43%)
41+ 2581
(35%)
2985
(41%)
705 (25%) 167 (36%) 459 (30%) 145 (34%) 7042
(35%)
Missing 0 74 0 66 0 0 140
Reported exposure
Heterosexual contact 2127
(100%)
1540
(100%)
2825 (100%) 236 (99%) 1057
(76%)
289 (99%) 8074
(96%)
Homosexual contact 0 (0%) 0 (0%) 0 (0%) 2 (1%) 299 (21%) 0 (0%) 301 (4%)
Injecting drug use 0 (0%) 0 (0%) 0 (0%) 0 (0%) 40 (3%) 3 (1%) 43 (< 1%)
Other/unknown 5231 5749 28 233 154 134 11529
Haemoglobin level at initiation (g/dL, within 90
days before intiation)
Median (IQR) 10.1
(9.0,11.5)
11.2
(9.6,12.8)
11.2
(10.0,13.0)
10.1 (9.4,
11.8)
12.2
(10.8,13.8)
12.0 (11.0,14.0) 10.9
(9.4,12.4)
> = 10 g/dL 4057
(55%)
5142
(71%)
2257 (79%) 304 (64%) 1317
(85%)
368 (86%) 13445
(68%)
7.5~ < 10 g/dL 2738
(37%)
1773
(24%)
517 (18%) 156 (33%) 206 (13%) 51 (12%) 5411
(27%)
6.5~ < 7.5 g/dL 365 (5%) 224 (3%) 46 (2%) 8 (2%) 18 (1%) 5 (1%) 666 (3%)
< 6.5 g/dL 198 (3%) 150 (2%) 33 (1%) 3 (1%) 9 (1%) 2 (< 1%) 395 (2%)
Haemoglobin test after initiation (up to year one)
Median number of tests (IQR) 1 (1,2) 1 (1,2) 2 (1,3) 1 (1,2) 3 (1,4) 3 (1,5) 1 (1,2)
Median days from initiation
to the first test (IQR) 217
(180,337)
212
(163,342)
294
(186,339)
104.5 (14,
210)
282
(194,336)
274 (170,331) 239 (175,
338)
CD4 count at initiation (cells/mm
3, within 90 days
before initiation)
Median (IQR) 136
(56,220)
101
(44,166)
87 (32,155) 148.5 (62,
228)
112
(35,204)
120 (50,212) 112
(45,187)
< = 50 1662
(24%)
1907
(28%)
904 (34%) 63 (22%) 451 (33%) 92 (27%) 5079
(27%)
51~100 1090
(15%)
1506
(22%)
565 (22%) 38 (13%) 214 (15%) 60 (18%) 3473
(19%)
101+200 2223
(31%)
2512
(36%)
833 (32%) 94 (32%) 263 (26%) 96 (28%) 6121
(33%)
201+ 2137
(30%)
946 (14%) 321 (12%) 95 (33%) 364 (26%) 93 (27%) 3956
(21%)
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in CA (Table 2).
Factors associated with developing anaemia 12 months
after cART initiation were (Table 2): female gender (33%
increase of risk compared with males); low baseline haemo-
globin level (significant increase of risk with decreasing
haemoglobin at baseline); low baseline CD4 count (signifi-
cant increase of risk with decreasing CD4 count at
baseline); advanced disease stage (30% increase of risk com-
pared with lesser disease stage); initial AZT-containing
cART (150% increase of risk compared with patients initi-
ating non-AZT-containing cART). Tuberculosis co-infec-
tion and using of TMP-SMX were statistically significant in
univariate analysis, but lost significance after adjustment.
Risks of anaemia by initial cART (AZT-containing or
not) by IeDEA region are plotted in Figure 3. In patients
Table 1 Patient characteristics at cART initiation (Continued)
Not available 246 418 230 181 158 85 1318
HIV RNA at initiation (copies/mL, within 90 days
before initiation)
Median 165600 5565 52702 4900 119500 91000 72274.5
(IQR) 31462,
550025
400, 39600 14041,
184563
< 400,
46155
30000,
413273
9000, 160000 17400,
270000
< 400 7 (5%) 5 (50%) 109 (8%) 3 (27%) 31 (5%) 17 (12%) 175 (7%)
400~10,000 10 (8%) 0 (0%) 157 (11%) 3 (27%) 55 (8%) 18 (13%) 240 (10%)
10,001~100,000 34 (26%) 4 (40%) 633 (46%) 3 (27%) 235 (35%) 57 (42%) 966 (41%)
100,001+ 81 (61%) 1 (10%) 491 (35%) 2 (19%) 357 (52%) 45 (33%) 977 (42%)
Not available 7226 7279 1463 460 872 289 19947
Disease stage: CDC 3 or WHO 4
No 3185
(74%)
6048
(90%)
2349 (83%) 160 (34%) 827 (53%) 138 (37%) 12707
(78%)
Yes 1118
(26%)
639 (10%) 491 (17%) 311 (66%) 723 (47%) 236 (63%) 3518
(22%)
Not known 3055 602 13 0 0 52 3722
Tuberculosis co-infection
No 6369
(87%)
5345
(73%)
2532 (89%) 17 (4%) 1240
(80%)
396 (92%) 15899
(80%)
Yes 989 (13%) 1944
(27%)
321 (11%) 454 (96%) 310 (20%) 30 (7%) 4048
(20%)
Use of TMP-SMX
No 2949
(40%)
2972
(41%)
— 330 (70%) 741 (48%) — 6992
(42%)
Yes 4409
(60%)
4317
(59%)
— 141 (30%) 809 (52%) — 9676
(58%)
Not known 0 0 2853 426 3279
Initial cART combination containing AZT
No 4787
(65%)
7000
(96%)
2099 (74%) 190 (40%) 938 (60%) 89 (21%) 15103
(76%)
Yes 2571
(35%)
289 (4%) 754 (26%) 281 (60%) 612 (40%) 337 (79%) 4844
(24%)
Initial cART combination containing d4T
No 2813
(38%)
291 (4%) 760 (27%) 297 (63%) 725 (47%) 341 (80%) 5227
(26%)
Yes 4545
(62%)
6998
(96%)
2093 (73%) 174 (37%) 825 (53%) 85 (20%) 14720
(74%)
Initial treatment combination (top 4 most
frequent)
d4T/3TC/NVP 2414
(33%)
5978
(82%)
415 (15%) 149 (32%) 560 (36%) 46 (11%) 9562
(48%)
d4T/3TC/EFV 1507
(20%)
919 (12%) 1668 (58%) 22 (5%) 111 (7%) 24 (6%) 4251
(21%)
AZT/3TC/EFV 1398
(19%)
54 (< 1%) 441 (15%) 52 (11%) 249 (16%) 261 (61%) 2455
(12%)
AZT/3TC/NVP 392 (5%) 201 (3%) 280 (10%) 224 (48%) 162 (11%) 20 (5%) 1279 (6%)
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AZT-containing cART had an increased risk of develop-
ing anaemia when compared with those initiating a
non-AZT-containing regimen (p < 0.001, respectively).
The difference between the AZT and non-AZT groups
in CA and CSA was not statistically significant after
adjusting for the factors just outlined (CA, p = 0.088;
CSA, p = 0.396).
Table 3 shows the proportions of patients with anae-
mia at month 12 after initiation of antiretroviral treat-
ment by baseline haemoglobin level and stratified by
initial AZT or d4T use. The table shows that for both
AZT and d4T, the proportion of patients with anaemia
is associated with baseline haemoglobin level. However,
in patients starting with AZT, the proportion of anaemic
patients remains high even in patients with baseline hae-
moglobin from 12 to < 13 g/dL (13%). The proportion
of anaemic patients is lower in patients stating d4T in
each category of baseline haemoglobin, typically those
above 11 g/dL.
Discussion
In this study that included six IeDEA regions and 34
HIV treatment cohorts, we found that the risk of devel-
oping anaemia within the first year on cART was asso-
ciated with female sex, low baseline haemoglobin, more
advanced immune-deficiency (clinically and immunolo-
gically) and receiving an initial cART containing AZT.
In addition, we found that d4T-containing regimens
were being used more commonly than AZT-containing
regimens, especially in patients with severe anaemia at
cART initiation.
An initial haemoglobin decrease of approximately 0.5
g/dL in the first three months was observed in patients
initiating AZT-containing cART, compared with an
immediate haemoglobin increase after initiation in
patients starting with non-AZT-containing cART. These
data are consistent with results from a meta-analysis of
six randomized trials in treatment-naïve patients receiv-
ing either AZT or d4T as part of the regimen [16]. In
this meta-analysis, haemoglobin levels decreased with
AZT-containing treatment by a mean of 0.4 g/dL and
0.2 g/dL at weeks 24 and 48, respectively, but increased
with d4T-containing treatment by 0.45 g/dL and 0.58 g/
dL, respectively. The DART study also reported low
haemoglobin measures at week 4, and grade 4 anaemia
(< 6.5 g/dL) occurring at week 12 following initiation of
an AZT-containing regimen [17].
The use of AZT+3TC and d4T+3TC as the preferred
NRTIs in a regimen has been advocated by WHO since
2000 and are the most common NRTI combinations
used in initial HIV treatment regimens in resource-lim-
ited settings [18,19]. Until recently, d4T was preferred
over AZT due to its lower requirement for laboratory
monitoring, lower cost, and availability in fixed-dose
combinations tablets, despite its poorer toxicity profile,
in association with lactic acidosis, lipodystrophy and
peripheral neuropathy. To avoid or minimize the d4T-
related long-term toxicity, in 2006, WHO recommended
a move away from d4T-containing regimens [20], and in
2009, emphasized this in advice on antiretroviral treat-
ment [21]. This recommendation was in agreement with
other treatment guidelines, such as those published by
the United States Department of Health and Human
Services [22] and the British HIV Association [23]. In
settings where d4T-containing regimens were used as
the major initial drugs, WHO recommended moves
towards AZT- or tenofovir (TDF)-based first-line
regimens.
Among patients included in this paper, the median
year of cART initiation was 2004-05 in the respective
IeDEA regions. The major initial cART regimen
0
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Figure 1 Proportions of AZT-containing cART by region and
baseline haemoglobin level.
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Figure 2 Mean change of haemoglobin since initiation of cART.
Zhou et al. Journal of the International AIDS Society 2012, 15:5
http://www.jiasociety.org/content/15/1/5
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(> = 10 g/dL)
No. Follow
up
No. Rate Univariate
analysis
Multivariate
analysis
patients (years) Anaemia (/100pys) HR p
value
HR (95%
CI)
p value
Total 13445 11893 1373 11.5
IeDEA region (analyses were stratified by IeDEA region)
Western Africa 4057 3361 612 18.2
Eastern Africa 5142 4825 320 6.6
Southern Africa 2257 2035 197 9.7
Central Africa 304 214 49 22.9
Asia-Pacific 1317 1156 136 11.8
Central & South America 368 302 59 19.5
Gender
Male 6000 5344 471 8.8 reference reference
Female 7445 6549 902 13.8 1.65 < 0.001 1.33
(1.18, 1.50)
< 0.001
Age (years, at initiation)
< = 30 2668 2342 328 14.0 reference reference
31~40 5697 5053 577 11.4 0.84 0.014 0.96
(0.83, 1.10)
0.532
41+ 4964 4420 455 10.3 0.78 0.001 0.96
(0.83, 1.11)
0.583
Missing 96 78 13 16.7 1.10 0.739 1.16
(0.64, 2.10)
0.622
Baseline haemoglobin (g/dL)
13+ 3826 3552 136 3.8 reference reference
12 to < 13 2726 2485 160 6.4 1.67 < 0.001 1.51
(1.19, 1.90)
0.001
11 to < 12 3389 2961 398 13.4 3.46 < 0.001 2.96
(2.42, 3.62)
< 0.001
10 to < 11 3504 2895 679 23.4 5.95 < 0.001 4.94
(4.06, 6.01)
< 0.001
CD4 count at initiation (cells/mm
3, within 90 days before
initiation)
101+ 7138 6408 598 9.3 reference reference
51~100 2224 1986 218 11.0 1.18 0.037 1.24
(1.06, 1.45)
0.007
< = 50 3187 2753 417 15.1 1.62 < 0.001 1.65
(1.45, 1.87)
< 0.001
Not available 896 746 140 18.8 1.99 < 0.001 1.71
(1.41, 2.08)
< 0.001
Disease stage: CDC 3 or WHO 4
No 8775 7930 761 9.5 reference reference
Yes 2263 1882 350 17.9 1.54 < 0.001 1.30
(1.13, 1.50)
< 0.001
Not known 2407 2081 262 12.6 0.80 0.005 0.86
(0.73, 1.00)
0.057
Tuberculosis co-infection
No 10958 9721 1098 11.3 reference reference
Yes 2487 2172 275 12.7 1.20 0.013 0.95
(0.81, 1.10)
0.496
Initial ARV combination containing AZT
No 9760 8988 716 8.0 reference reference
Yes 3685 2905 657 22.6 12.43 < 0.001 2.51
(2.22, 2.83)
< 0.001
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Page 7 of 12Table 2 Risk of anaemia (?<? 10 g/dL) within 12 months after ART initiation among patients with normal haemoglobin
(> = 10 g/dL) (Continued)
Initial ARV combination containing d4T
No 3906 3093 677 21.9 reference reference
Yes 9539 8800 696 7.9 0.47 < 0.001 0.82
(0.54, 1.25)
0.356
Use of TMP-SMX
No/Not known 7330 6481 706 10.9 reference reference
Yes 6115 5412 667 12.3 1.14 0.032 1.01
(0.89, 1.14)
0.929
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Figure 3 Risk of anaemia (< 10 g/dL) by initial cART and region.
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Page 8 of 12contained d4T rather than AZT, which reflects to a
large extent the true situation in low- and middle-
income countries with limited resources. Moreover, in
each of the IeDEA regions, patients with severe anaemia
were generally initiated with a non-AZT-containing
cART, which was most likely due to the well-established
association between anaemia and AZT use [5,16,24].
The crude rate of acquiring anaemia among patients
with normal haemoglobin at cART initiation did vary
somewhat across the IeDEA regions. This might be due
to sampling mechanisms, or biases due to different pat-
terns of haemoglobin testing in each region. For exam-
ple, at cART initiation and during the course of
treatment, patients who had haemoglobin tests might
have been selected for testing because they were consid-
ered at higher risk of developing anaemia by the local
clinician. However, the risks of severe anaemia seemed
relatively rare and consistent across the regions. Similar
finding was found previously in patients from Uganda
and Zimbabwe in the DART trial [17].
Female sex, low baseline haemoglobin, more advanced
immune-deficiency (clinically and biologically) and
initial cART-containing AZT were associated with the
risk of acquiring anaemia within 12 months of starting
cART. These risk factors were reported in previous stu-
dies [3,5-7,17]. However, the majority of the patients
across the IeDEA regions did not have HIV viral load
measurement prior to cART initiation, and weight and
height data were not generally available across the
regions. Consequently, we could not examine the effects
of HIV viral load and body mass index on the risk of
acquiring anaemia. The use of TMP-SMX was signifi-
cant in univariate analysis, which might have to do with
other infection and the need for prophylaxis since TMP-
SMX rarely causes anaemia [25].
We acknowledge several limitations to our study. First,
the selection of patients with at least a baseline and one
follow-up measurement of haemoglobin might have
introduced a bias of selection: patients with documented
haemoglobin measurements are more likely to be at risk
of anaemia than patients without assessment. In princi-
pal, rapid onset of severe, life-threatening anaemia that
resulted in loss to follow up and death without a
subsequent haemoglobin measurement is a potential
scenario in severely resource-limited settings.
Moreover, as this is an observational study, measure-
ments of haemoglobin might not be comparable in
every participating country. In addition, important
determinants of anaemia, such as body mass index,
nutrition intake and malaria status, were not available in
the current data assembled for analysis, which made the
direct comparison of the risk of anaemia between
IeDEA regions difficult, if not impossible, to interpret.
Consequently we stratified the region in the Cox regres-
sion model to assess the risk factors.
Conclusions
With the continued rapid scaling up of cART, there is a
need to monitor treatment-related toxicity, especially in
countries with limited resources and where alternative
treatments are not readily available. We found that
treating patients earlier, with less immune-deficiency,
and with a non-AZT-containing regimen are the only
modifiable risk factors associated with anaemia. In coun-
tries where TDF-based NRTI regimens are not widely
available, a short-term treatment of non-AZT-contain-
ing regimens (mostly d4T-containing), followed by a
switch to AZT, is worth investigating in terms of effi-
cacy, short- and long-term tolerability, and disease out-
comes [26-28]. This could be potentially beneficial for
patients at risk of developing anaemia, e.g., female gen-
der, patients with low CD4 counts and patients with
advanced disease stage. In addition, routine haemoglobin
monitoring is recommended in patients initiating with
AZT-containing cART, typically at week 4, 8, 12, or at
least every three months [2,17].
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